

# Basal Cell Carcinoma Therapeutic Pipeline Market Review, H2 2016

*Basal Cell Carcinoma Treatment Pipeline Review H2 2016*

PUNE, INDIA, October 14, 2016

/EINPresswire.com/ -- The report provides comprehensive information on the therapeutics under development for [Basal Cell Carcinoma](#) (Basal Cell Epithelioma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects.



WISE GUY  
REPORTS

Norah Trent Partner Relations & Marketing Manager

✉ sales@wiseguyreports.com

☎ Ph: +1-646-845-9349 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>

🐦 <https://twitter.com/WiseGuyReports>

📘 <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Wise.Guy.

Get Sample Report @ <https://www.wiseguyreports.com/sample-request/477388-basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h1-2016>

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

## Scope

- The report provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma

## (Basal Cell Epithelioma)

- The report reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics and enlists all their major and minor projects
- The report assesses Basal Cell Carcinoma (Basal Cell Epithelioma) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma)

## Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Buy 1-User PDF @ [https://www.wiseguyreports.com/checkout?currency=one\\_user-USD&report\\_id=477388](https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=477388)

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage	7
Basal Cell Carcinoma (Basal Cell Epithelioma) Overview	8
Therapeutics Development	9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview	9
Pipeline Products for Basal Cell Carcinoma (Basal Cell Epithelioma) - Comparative Analysis	10
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Development by Companies	11
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics under Investigation by Universities/Institutes	13
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Products Glance	14
Late Stage Products	14
Clinical Stage Products	15
Early Stage Products	16
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Development by Companies	17
Basal Cell Carcinoma (Basal Cell Epithelioma) - Products under Investigation by Universities/Institutes	18
Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development	19
Biofrontera AG	19
Biosceptre (Aust) Pty Ltd	20
Genextra S.p.a.	21
Ignyta, Inc.	22
Laboratories Ojer Pharma S.L.	23
MediGene AG	24
Merck & Co., Inc.	25
Novartis AG	26
Provectus Biopharmaceuticals, Inc.	27
Redx Pharma Plc	28
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.	29
Transgene SA	30
Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment	31
Assessment by Monotherapy Products	31
Assessment by Combination Products	32
Assessment by Target	33

Access Report @ <https://www.wiseguyreports.com/reports/477388-basal-cell-carcinoma-basal-cell-epithelioma-pipeline-review-h1-2016>

Follow Us:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports>

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

wiseguyreports

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/349316421>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.